natgillin/translations-raw huggingface dataset:
It is seen how the invention has reached the above-described aim and objects, there being provided a ski boot which, thanks to the possibility of adjusting both the length of the shell and the height of the cuff, is adaptable in an optimum manner to the specific dimensions of the foot and of the leg of the user, guarantee to the same an high comfort-fit. 
Vidljivo je kako se s izumom postiže gore opisan cilj i predmet, kako je ovdje osigurana cipela za skijanje, koja se zahvaljujući mogućnosti podešavanja obojeg, kako duljine plašta, tako također i visine manžete, može prilagoditi na optimalan način prema specifičnim dimenzijama stopala i noge korisnika, te jamčiti njezinu visoku udobnost i točno pristajanje.
The cocoa powder according to claims 4 to 7, wherein in said method the first vapor phase exiting the first mixing device in step (e1) is fed into the suspension before or during steps (b) and (c). 
Postupak obrade zrna kakaa ili komadića zrna kakaa u skladu s patentnih zahtjeva 5 do 8, naznačen time što se prvu parovitu fazu koja izlazi iz prvog uređaja za miješanje u koraku (e1) dodaje u suspenziju prije ili tijekom koraka (b) 1 (c).
It required 25 ml of extra purified water. 
To je zahtijevalo 25 ml dodatno pročišćene vode.
The pharmaceutical kit in accordance with claim 9, wherein the second compartment comprises the disodium salt form of the compound N -[4-[2-(2-amino-4,7-dihydro-4-oxo-1 H -pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-Glutamic acid. 
Farmaceutska garnitura prema zahtjevu 9, naznačena time, da drugi odjeljak sadrži solni oblik dinatrija od spoja N-[4-[2-(2-amino-4,7-dihidro-4-okso-1H-pirolo[2,3-d]pirimidin-5-il)etil]benzoil]-1-glutaminska kiselina.
The composition of claim 1, wherein said mature human KLK1 polypeptide(s) comprise an amino acid sequence having at least about 95% sequence identity to amino acid residues 25-262 of SEQ ID NO:1 or SEQ ID NO:2. 
Pripravak u skladu s patentnim zahtjevom 5, naznačen time što navedeni jedan ili više polipeptida KLK1 sadrže aminokiselinski slijed koji ima istovjetnost slijeda od najmanje 95% s aminokiselinskim ostacima 25-262 iz SEQ
Using the process described at point 1), the kiln described at point 2) and the firing cycle described at point 3), the achievement of a product of transformation of the asbestos containing materials, composed of non-fibrous crystalline Ca-, Mg-rich silicates with Fe and Al impurities, not hazardous for the human and animal health, to be ground and recycled as a raw material for the formulation of a number of different industrial products such as ceramic pigments, bricks, and plastic materials. 
Proces prema zahtjevu 1, naznačen time da se spomenuti otpad koji sadrži azbest transformira u materijal koji se sastoji od nevlaknastih kristalinskih silikata s bogatim sadržajem Ca, Mg s Fe i A) nečistoća, pri čemu se spomenuti materijal melje i reciklira za uporabu kao sirovinski materijal za formulaciju niza industrijskih proizvoda kao što su keramički pigmenti, opeke i plastični materijali.
A method as claimed in any of Claim 10 to 12, wherein the amount of base added is more than sufficient to fully neutralise the polycarboxylic acid polymer. 
Postupak za koji se traži zaštita patentom u patentnom zahtjevu 13, ili patentnom zahtjevu 14, pri čemu je dodana količina baze više nego dovoljna da potpuno neutralizira polimer polikarboksilne kiseline.
2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-(4-(4-(5-fluoropyrimidin-2-yl)piperazin-1-yl)phenyl)-2-oxoacetamide or an agriculturally acceptable salt thereof; optionally together with a second antifungal agent, as an agricultural fungicide. 
-(1,5-dimetil-3-fenil-1H-pirol-2-il)-N-(4-(4-(5-fluoropirimidin-2-il)piperazin-1-il)fenil-2-oksoacetamid ili njegova poljoprivredno prihvatljiva sol; opcionalno zajedno s drugim antifungalnim sredstvom, kao poljoprivrednog fungicida.
The lyophilised formulations of this invention can be reconstituted and diluted to give a composition of this invention in the form of a solution ready for intravenous injection. 
Liofilizirani oblici ovog izuma mogu biti rekonstruirani i razrijeđeni tako da daju smjesu ovog izuma u obliku otopine spremne za intravenoznu injekciju.
Said bonding spots and/or bonding areas are arranged immediately adjacent to the lower edge of said annular upper wall section of the cup body, where an upper shoulder is formed. 
Također je moguće staviti navedene točke spajanja i/ili područja spajanja neposredno uz donji rub navedenog gornjeg dijela stijenke tijela čaše, gdje je načinjeno gornje izbočenje.
and R7 are independently hydrogen or fluoro; -Z-EWG- is each ring optionally substituted with one or two substituents independently selected from alkyl, hydroxy, or halo, and the carbonyl and sulfonyl group in, is attached to -C(CN)=CHRc; and Rc is alkyl, haloalkoxy, substituted alkyl, cycloalkyl, cycloalkyleneNRdRe or cycloalkylene(alkylene)NRdRe (where Rd and Re are independently hydrogen, alkyl, or cycloalkyl), or 3 to 6 membered saturated monocyclic heterocyclyl containing one or two heteroatoms selected from N, O, or S and optionally substituted with one or two substituents selected from hydroxy, alkyl or fluoro; 
i R7 su zasebno vodik ili fluoro; [image] supstituiran s jednim ili dva supstituenta zasebno odabrana iz alkila, hidroksi ili halo, a [image] Rc je alkil, haloalkil, supstituirani alkil, cikloalkil, cikloalkilenNRdRe ili cikloalkilen(alkilen)NRdRe(pri čemu su Rd i Re zasebno vodik, alkil ili cikloalkil) ili zasićeni monociklički heterociklil od 3 do 6 članova koji sadrži jedan ili dva heteroatoma odabrana iz N, O ili S i opcionalno supstituiran s jednim ili dva supstituenta odabrana iz hidroksi, alkila ili fluoro; koji se sastoji od:
The solid oral extended release pharmaceutical dosage form of any one of claims 84 and 85, wherein the extended release matrix formulation resists a work of at least about 0.06 J without cracking. 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1, 2 ili 3, naznačen time da je formulacija matrice s produljenim otpuštanjem otporna na rad od barem oko 0.06 J bez pucanja.
Preferably, the width of the beam-like blocks of wood is > 60 mm, preferably > 120 mm, whereby particularly a width of approximately 150 mm has to be outlined. 
Poželjno je da je širina blokova od drva koji imaju oblik grede > 60 mm, poželjno > 120 mm, pri čemu se treba naročito izdvojiti duljina od približno 150 mm.
a tearable membrane (7) closing the hopper (5) and the vessel (2). 
- pokrov kojeg se može probušiti (7), koji zatvara kraj izlaza za pražnjenje (6) i otvorenog kraja (4) posude (2).
another respiratory virus anti-viral, such as an anti-influenza and/or anti-rhinovirus compound; and/or 
drugi resipratorni, protuvirusni spoj, kao što je spoj protiv gripe i/ili rinovirusa; i/ili
The expression “stable” refers to a phase which does not transform spontaneously under the conditions required for transforming the filler ingredient from the first metastable phase. 
Izraz "stabilan" odnosi se na fazu koja se ne transformira spontano pod uvjetima potrebnim za transformaciju materijala za punjenje iz prve metastabilne faze.
The method according to claim 1, wherein the combination contains isobutylamides from Echinacea angustifolia and gingerol from Zingiber officinale in weight ratios ranging from 1:1 to 1:0.5. 
Kombinacija za upotrebu kao što je prijavljena u patentnom zahtjevu 3, naznačena time da sadrži izobutilamide iz Echinacea angustifolia i gingerol i Zingiber officinale u masenom omjeru raspona od 1:1 do 1:0.5.
The CB1 receptor is highly expressed in the central and peripheral nervous systems (M. Glass, et al., Neuroscience, 77, 299-318 (1997)), while the CB2 receptor is highly expressed in immune tissue, particularly in spleen and tonsils. 
CB-1 receptor se intenzivno ekspresira u središnjem i perifernom živčanom sustavu (M. Glass, et al., Neuroscience, 77, 299-318 (1997)), dok se CB-2 receptor intezivno ekspresira u imunim tkivima, naročito u slezeni i krajnicima.
A method according to claim 3, wherein a Dummy Frame Insertion mode is activated in said modulators (5,6). A method according to one or more of claims 1 to 4, wherein the transmission rate adapter system is disabled in said modulators (5,6). 
Metoda prema patentnom zahtjevu 3, gdje režim umetanja lažnog okvira je aktiviran u navedenim modulatorima Metoda prema jednom ili više od patentnih zahtjeva 1 do 4, gdje sistem adaptera brzine prijenosa je onemogućen u navedenim modulatorima (5,6).
The polypeptide of any one of claims 1 to 4, wherein the polypeptide is selected from the group consisting of SEQ ID: 2, (SEQ ID NO: 4, SEQ ID NO. 
Sastav iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu polipeptid ima slijed kako je navedeno u SEQ ID NO:2 1li SEQ ID NOÂ«4.
The cyclic peptide according to any of claims 1-4, further comprising a cargo moiety, wherein the cargo moiety comprises a detectable moiety, a therapeutic moiety, a targeting moiety, or a combination thereof. 
Ciklični peptid prema bilo kom od patentnih zahtjeva 1-4, koji dodatno sadrži kargo-fragment, naznačen time, što kargo-fragment sadrži detektabilni fragment, terapijski fragment, fragment koji ciljno djeluje, ili njihovu kombinaciju.
The amount of water in the emulsion or composition can range from about 15 percent to 95 weight percent, preferably from about 45 to 75 percent, most preferably from about 60 percent to about 75 percent. 
Količina vode u emulziji ili pripravku se može kretati od oko 15 postotaka do 95 masenih postotaka, poželjno od oko 45 do 75 postotaka, najpoželjnije od oko 60 postotaka do oko 75 postotaka.
a BICM (Bit Interleaved Coding and Modulating) module configured to decode the signaling data in the at least one preamble symbol by a shortened and punctured LDPC (Low Density Parity Check) decoding scheme and to decode data in the data slice, wherein a signaling block having the signaling data is repeated in the at least one preamble symbol in a frequency domain by a bandwidth, wherein the bandwidth of the signaling block corresponds to a number of active subcarriers assigned to a single channel. 
Uređaj za prijam radiotelevizijskog signala, naznačen time, što uređaj obuhvaća: sredstva za prijam signalnog okvira koji uključuje simbole preambule i barem jedan podatkovni odsječak temeljen na simbolu podatkovnog servisa; sredstva za demodulaciju primljenog signalnog okvira korištenjem metode multipleksiranja s ortogonalnom podjelom frekvencija (OFDM); sredstva za premapiranje simbola preambule u podatkovne bitove preambule, te simbole podatkovnog servisa u bitove podatkovnog servisa; i sredstva za dekodiranje bitova preambula korištenjem skraćene i bušene LDPC (provjera pariteta niske gustoće) sheme dekodiranja; pri čemu su simboli preambule podijeljeni u frekvencijske osi u blokove sloja 1 (L1) iste širine pojasa, a širina pojasa pojedinog LI bloka odgovara jednom od 3408 podnosilaca pridijeljenih jednom kanalu.
A sealable container according to embodiment 1, wherein the base and the continuous side wall are clear. 
Posuda prema patentnom zahtjevu 1, pri čemu su osnova i kontinuirani bočni zid prozirni.
The method of claims 1-5, comprising the subsequent steps of adding a killed whole-cell or acellular pertussis component(s) and a pharmaceutically acceptable excipient. 
Postupak u skladu s patentnim zahtjevima 1-5, naznačen time što uključuje naknadne korake dodavanja jedne ili više cjelostaničnih ili nestaničnih komponenata umrtvljenog uzročnika hripavca i farmaceutski prihvatljivu podlogu.
The low intensity sweetener may be present in an amount up to 40 weight %, in particular from 10 to 40 weight %, preferably from 10 to 30 weight % of the sugar replacement composition. 
Sladilo male slatkoće može biti prisutno u količini do 40 težinskih %, preciznije, 10 do 40 težinskih %, a prednost se daje količini od 10 do 30 težinskih % u sastavini koja zamjenjuje šećer.
The device of any one of claims 1 to 3, wherein the hemostatic material is a clay material. The device of any one of claims 1 to 4, wherein the hemostatic material comprises attapulgite, bentonite, kaolin, kaolinite, or combinations of the foregoing materials. 
Uređaj prema patentnom zahtjevu 1, naznačen time što je glineni materijal odabran iz skupine koja se sastoji od atapulgita, bentonita, kaolina, kaolinita, te od kombinacija prethodnih materijala.
The compound according to claim 17, wherein said compound is in the form of a salt. 
Spoj, kako je dan prema zahtjevu 17, naznačen time, da navedeni spoj je u obliku soli.
A benzazepine compound represented by general formula (1) wherein R1 is a group of (1-5): 
Spoj benzazepina, naznačen time, da je predstavljen općom formulom (1) [image] gdje:
• Ar1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; 
Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, svaki nesupstituiran ili supstituiran na članu ugljik prstena sa jednom ili dvije Ra funkcionalne grupe;
The method of claim 1, wherein the pH of said reduced pH sample in step (c) is adjusted to a pH of about 4.5 to about 6.5. 
Postupak sukladno patentnom zahtjevu 1 ili 2, naznačen time što navedeni uzorak s reduciranim pH u koraku (c) ima pH od oko 3.5.
A process according to any preceding claim, wherein the coating additionally comprises a second compound selected from one or more fatty acids and one or more salts of a fatty acid, and combinations thereof. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što obloga dodatno sadrži drugi spoj, kojeg se bira između jedne ili više masnih kiselina 1 jedne ili više soli masnih kiselina, te njihovih kombinacija.
The method as claimed in claim 12, wherein the liquid substance is applied with a Piezo ink head. 
Postupak prema zahtjevu 10 ili 11, naznačen time što je tekuća supstanca izložena infracrvenom svijetlu (23) ili toplom zraku.
An isolated nucleic acid encoding a humanized anti-a2B1 integrin antibody of claim 1. 
Izolirana nukleinska kiselina koja kodira humanizirano anti-a2B1 integrin protutijelo prema zahtjevu 1.
1969 (corresponds to the numbering of the sequence which is represented by SEQ ID NO.6 as shown in Figure 2). 
20, (ii) slijed H-CDR2, koji je 36% ili više istovjetan slijedu H-CDR2 prikazanom u SEQ ID NO.
a repetition means (1915-L1) configured to repeat the constellation values corresponding to L1 signaling data and the Layer 1 header mapped into the at least one OFDM symbol; 
sredstvo za ponavljanje (1915-L1) konfigurirano za ponavljanje mapiranih konstelacijskih vrijednosti koje odgovaraju signalnom podatku razine 1 i zaglavlju razine 1;
Examples of such transformations include, but are not limited to, transformation of an —OH group to a phosphate by methods known to those skilled in the art, and described in Haftendorn, R., Ulbrich-Hoffmann, R. Tetrahedron 1995, 51 (4), 1177-1186, Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985) and references therein. 
Primjeri takvih transformacija uključuju, ali bez ograničenja, transformaciju -OH skupine u fosfat primjenom postupaka koji su poznati osobama iz struke i opisani u Haftendorn, R., Ulbrich-Hoffmann, R. Tetrahedron 1995, 51 (4), 1177-1186, Design of Prodrugs, urednika H. Bundgaard, (Elsevier, 1985) i referencama koje su tamo navedene.
that a formwork skin element (8) or a plurality of formwork skin elements (8) is/are injection-molded or compression-molded from a plastics material; and that 
što pokrovni element oplate (8) ili više pokrovnih elemenata oplate (8) je/su načinjeni injekcijski ili načinjeni tlačenjem iz plastičnog materijala; te što
wherein (II) the step of storing the polypropiolactone occurs at the second location; or: 
(B) korak skladištenja polipropiolaktona se provodi na drugoj lokaciji.
reacting a compound of the formula IV A-CH2—X IV wherein A is as previously defined and X is a leaving group, with a compound of the formula V wherein Z, n, R3 and R4 are as previously defined; or 
(b) reakcija spoja formule IV A-CHo-X IV gdje A je kao prethodno definiran i X je izlazeća skupina, sa spojem formule V gdje Z,n, R* i R* su kao prethodno definirani; ili
For example, a second chiral centre exists in those compounds wherein B=—CH2CHR7— wherein R7 is a C1-3 alkyl or alkoxy group. 
Na primjer, drugi kiralni centar postoji u onim spojevima gdje B = pri čemu R' je C,. alkil ili alkoksi skupina.
Some embodiments of the present invention pertain to compounds wherein X is N. 
Pripravak u skladu sa zahtjevom 1, naznačen time, da X je N.
is hydrogen or C1-6alkyl; is hydrogen or C1-6alkyl; or R12 and R13 taken together with the nitrogen atom to which they are substituted form imidazolyl. A compound according to any one of claims 1 to 5 wherein R5 is C2-6alkenyl, C2-6alkynyl substituted with Het, Ar, Het; 
R'? je vodik ili C,ealkil; R3 je vodik ili C,.galkil; ili R!? i R'? uzeti zajedno sa atomom dušika na koji su supstituirani formiraju imidazolil, Spoj prema bilo kojem od zahtjeva 1 do 5 naznačen time da R? je Cogalkenil, C> galkinil supstituiran sa Het, Ar, Het;
the compound of the formula I as drawn below or a pharmaceutically acceptable salt, solvate, hydrate or morphological form thereof, 
spoj formule I [image] I ili njegovu farmaceutski prihvatljivu sol, njegov solvat, hidrat ili njegov morfološki oblik,
The combination of claim 1, wherein the first agent is 2-acetylnaphtho[2,3 -b]furan-4,9-dione or a pharmaceutically acceptable salt or solvate thereof. 
Kombinacija iz patentnog zahtjeva 1, pri čemu je prvi agens 2-acetilnafto[2,3-b]furan-4,9-dion ili njegova farmaceutski prihvatljiva sol ili solvat.
multiple administrations are given and there is a low level of variability in absorption of the composition by the individual for the different administrations, or 
daju višestruke primjene i postoji niska razina varijabilnosti u apsorpciji sastava pojedinca za različite primjene, ili
The device of claim 1, wherein the conductive element further comprises a conducting adhesive applied to a first surface thereof, wherein the conductive element is adhered to the adhesive via the first surface. 
Uređaj prema zahtjevu 1, naznačen time da vodljivi element nadalje sadrži vodljivo ljepilo koje je primijenjeno na njegovu prvu površinu, pri čemu je vodljivi element pričvršćen na ljepilo preko prve površine.
is optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted pyridazinyl or optionally substituted thiophenyl; is: 
R* je opcijski supstituiran fenil, opcijski supstituiran piridinil, opcijski supstituiran pirimidinil, opcijski supstituiran piridazinil ili opcijski supstituiran tiofenil;
A combination according to claim 3, wherein the long-acting B2 agonist is selected from the group comprising formoterol, salmeterol and QAB-149 optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija sukladno patentnim zahtjevima 3 ili 4, naznačena time, da je B2 agonist odabran iz skupine koji sadrži formoterol, salmeterol 1 OAB-149 opcionalno u obliku njihovih racemata, enantiomera, diastereomera 1 njihovih smjesa te opcionalno njihovih farmaceutski-kompatibilnih kiselinskih adicijskih soli.
The pharmaceutical composition for oral administration according to claim 1 or 2, wherein 70% or more of solifenacin, is dissolved for 15 minutes. 
Tableta za oralnu primjenu prema zahtjevu 1 ili 2, gdje se 65% ili više solifenacina otpušta nakon 15 minuta.
The disposable component of claim 14 wherein the infusion/aspiration tip extends in a direction along the longitudinal axis to a point adjacent to the infusion port when the disposable component is coupled to the instrument. 
Instrument prema zahtjevu 4, naznačen time, da se bliži kraj infuzijskog/aspiracijskog vrha (104) proteže u smjeru uzduž uzdužne osi do točke koja graniči s infuzijskim priključkom (106).
The animals were placed in plexiglass cages under a video camera in a room with low light intensity (maximum 50 lux). 
Životinje su smještene u pleksiglas kaveze uz video kameru u prostoriju s niskim intenzitetom svjetla (maksimum 50 luksa).
Check the bulk container to confirm the identity of its contents. 
Pakovanje Provjeriti kontejner da bi se potvrdio identitet njegovog sadržaja.
Production line according to claim 1, characterized in that prior to printing the upper surfaces of the panels are treated with sealants. 
Proizvodna linija prema zahtjevu 1, naznačena time što se prije ispisivanja gornje površine ploča obrađuju sredstvima za brtvljenje.
Solid NaOH (1.6 g, 40 mmol) was added and the resulting mixture was heated at 50° C. overnight. The mixture was cooled to ambient temperature and the volatiles were evaporated. 
Doda se čvrsti NaOH (1,6 g, 40 mmol), a dobivenu smjesu grije preko noći na 50 *C. Smjesu se ohladi na temperaturu okoliša, a hlapive tvari otpari.
Placebo (54 weeks) 
(54) Naziv izuma:
fibrillating the cellulose fibres in an aqueous environment in the presence of the at least one filler and/or pigment until the fibres are at least partially broken down to primary fibrils and a nano-fibrillar cellulose gel is formed, wherein the formation of the gel is verified by monitoring the viscosity of the mixture in dependence of the shearing rate, wherein the viscosity decrease of the mixture upon step-wise increase of the shearing rate is stronger than the corresponding viscosity increase upon subsequent step-wise reduction of the shearing rate over at least part of the shear rate range as shearing approaches zero. 
fibrilacije celuloznih vlakana u vodenom mediju u prisutnosti najmanje jednog punila i/ili pigmenta, dok se ne dobije gel od nanofibrilarne celuloze, gdje se dobivanje gela potvrdi praćenjem viskoznosti smjese ovisnosti o brzini sječenja, gdje je smanjenje viskoznost smjese prilikom postupnog povećavanja brzine sječenja je veće od odgovarajućeg povećavanja viskoznosti prilikom naknadnog postupnog smanjivanja brzine sječenja preko u najmanju ruku dijela raspona brzine sječenja dok se sječenje približuje nuli.
15 and 16, these openings 1501, 1601, 1602 are generally circular in shape. 
Kako je prikazano na Slikama 15i 16, ti otvori 1501, 1601, 1602 obično su kružnog oblika.
Process for the preparation of a biomimetic bone substitute and its uses 
POSTUPAK ZA PRIPREMU BIOMIMETIČKE ZAMJENE ZA KOST | NJEGOVE PRIMJENE
A compound of claim 1, of Formula (Ia) 
Spoj iz patentnog zahtjeva 1, sa Formulom (Ia) N-O
Use of a chimeric peptide according to claim 13 or 14, wherein the pharmaceutical composition is to be administered by an administration route selected from the group consisting of intraperitoneal, nasal, intramuscular, subcutaneous, cutaneous, intravenous, oral and patch delivery. 
Uporaba prema zahtjevu 9, naznačena time, da je farmaceutski pripravak namijenjen za davanje putem za davanje koji je odabran iz skupine koja sadrži intraperitonealno, nazalno, intravenozno, oralno davanje i davanje putem flastera.
The cells are then incubated at 37° C. for 3 days. For assay of an GnRH antagonist, the incubated cells are first washed with 0.1% BSA/McCoy's 5A medium once, followed by addition of the test sample plus 1 nM GnRH in 200 ul 0.1% BSA/McCoy's 5A medium in triplicate wells. 
Stanice su zatim inkubirane 3 dana na 37 *C. Kod ispitivanja antagonista GnRH inkubirane stanice su najprije jednom isprane smjesom 0,1 % BSA/McCoyev međij SA, a zatim je dodan ispitivani uzorak, uz dodatak 1 nM GnRH u 200 ul smjese 0,1 % BSA/McCoyev medij SA u jažice u triplikatu.
4-Methyl-5-(4-pyridazinyl)-2,4-dihydro-3 H- 1,2,4-triazole-3-thione, as intermediate in the preparation of the compound of formula (I) according to claim 5. 
\ 1 naznačen time što je međuprodukt u dobivanju spoja formule (1) u skladu s patentnim zahtjevom 7.